Lena E Friberg

List of Publications by Year
in descending order

168 papers	7,357 citations	53794 45 h-index	66911 78 g-index
173 all docs	173 docs citations	173 times ranked	6715 citing authors

#	Article	IF	Citations
1	InÂvivo fitness of carbapenem-resistant Acinetobacter baumannii strains in murine infection is associated with treatment failure in human infections. Clinical Microbiology and Infection, 2022, 28, 73-78.	6.0	1
2	Continuous infusion of piperacillinâ€tazobactam significantly improves target attainment in children with cancer and fever. Cancer Reports, 2022, 5, e1585.	1.4	2
3	Large-scale WGS of carbapenem-resistant <i>Acinetobacter baumannii</i> isolates reveals patterns of dissemination of ST clades associated with antibiotic resistance. Journal of Antimicrobial Chemotherapy, 2022, 77, 934-943.	3.0	5
4	Population Pharmacokinetics of Flucloxacillin In Bone and Soft Tissueâ€" Standard Dosing is Not Sufficient to Achieve Therapeutic Concentrations. Pharmaceutical Research, 2022, 39, 1633-1643.	3.5	2
5	Anti-cancer treatment schedule optimization based on tumor dynamics modelling incorporating evolving resistance. Scientific Reports, 2022, 12, 4206.	3.3	4
6	Pulmonary and systemic pharmacokinetics of colistin methanesulfonate (CMS) and formed colistin following nebulisation of CMS among patients with ventilator-associated pneumonia. International Journal of Antimicrobial Agents, 2022, 59, 106588.	2.5	7
7	Model-Based Characterization of the Bidirectional Interaction Between Pharmacokinetics and Tumor Growth Dynamics in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab. Clinical Cancer Research, 2022, 28, 1363-1371.	7.0	2
8	Translational inÂvitro and inÂvivo PKPD modelling for apramycin against Gram-negative lung pathogens to facilitate prediction of human efficacious dose in pneumonia. Clinical Microbiology and Infection, 2022, 28, 1367-1374.	6.0	7
9	Pharmacokinetic/pharmacodynamic models for time courses of antibiotic effects. International Journal of Antimicrobial Agents, 2022, 60, 106616.	2.5	11
10	Research priorities towards precision antibiotic therapy to improve patient care. Lancet Microbe, The, 2022, 3, e795-e802.	7.3	17
11	Efficacy of EBL-1003 (apramycin) against Acinetobacter baumannii lung infections in mice. Clinical Microbiology and Infection, 2021, 27, 1315-1321.	6.0	21
12	Modelâ€Informed Drug Development for Antimicrobials: Translational PK and PK/PD Modeling to Predict an Efficacious Human Dose for Apramycin. Clinical Pharmacology and Therapeutics, 2021, 109, 1063-1073.	4.7	20
13	Pivotal Role of Translation in Antiâ€Infective Development. Clinical Pharmacology and Therapeutics, 2021, 109, 856-866.	4.7	19
14	Modelâ€Informed Drug Development for Antiâ€Infectives: State of the Art and Future. Clinical Pharmacology and Therapeutics, 2021, 109, 867-891.	4.7	41
15	Excluded versus included patients in a randomized controlled trial of infections caused by carbapenem-resistant Gram-negative bacteria: relevance to external validity. BMC Infectious Diseases, 2021, 21, 309.	2.9	4
16	From Therapeutic Drug Monitoring to Modelâ€Informed Precision Dosing for Antibiotics. Clinical Pharmacology and Therapeutics, 2021, 109, 928-941.	4.7	131
17	Tumor growth inhibition modeling of individual lesion dynamics and interorgan variability in HER2â€negative breast cancer patients treated with docetaxel. CPT: Pharmacometrics and Systems Pharmacology, 2021, 10, 511-521.	2.5	8
18	Dr. Hartmut Derendorf, PhD, a worldâ€renowned expert in pharmacokinetics and pharmacometrics (1953â€"2020). CPT: Pharmacometrics and Systems Pharmacology, 2021, 10, 527-528.	2.5	0

#	Article	IF	Citations
19	Multistate model for pharmacometric analyses of overall survival in HER2‑negative breast cancer patients treated with docetaxel. CPT: Pharmacometrics and Systems Pharmacology, 2021, 10, 1255-1266.	2.5	13
20	CPT: Pharmacometrics & Systems Pharmacology â€" Inception, Maturation, and Future Vision. CPT: Pharmacometrics and Systems Pharmacology, 2021, 10, 649-657.	2.5	6
21	Effect of Scalp Cooling on the Pharmacokinetics of Paclitaxel. Cancers, 2021, 13, 3915.	3.7	2
22	Antibacterial activity of apramycin at acidic pH warrants wide therapeutic window in the treatment of complicated urinary tract infections and acute pyelonephritis. EBioMedicine, 2021, 73, 103652.	6.1	15
23	Tissue Type Differences in ABCB1 Expression and Paclitaxel Tissue Pharmacokinetics in Patients With Esophageal Cancer. Frontiers in Pharmacology, 2021, 12, 759146.	3.5	5
24	Acute bacterial or viral infectionâ€"What's the difference? A perspective from PKPD modellers. Clinical Microbiology and Infection, 2020, 26, 1133-1136.	6.0	6
25	Reply to Wilson et al. Clinical Infectious Diseases, 2020, 71, 1358-1359.	5.8	0
26	Colistin Resistance Development Following Colistin-Meropenem Combination Therapy Versus Colistin Monotherapy in Patients With Infections Caused by Carbapenem-Resistant Organisms. Clinical Infectious Diseases, 2020, 71, 2599-2607.	5.8	10
27	Pharmacometrics and Systems Pharmacology 2030. Clinical Pharmacology and Therapeutics, 2020, 107, 76-78.	4.7	18
28	Extension of Pharmacokinetic/Pharmacodynamic Time-Kill Studies To Include Lipopolysaccharide/Endotoxin Release from Escherichia coli Exposed to Cefuroxime. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	13
29	How preclinical infection models help define antibiotic doses in the clinic. International Journal of Antimicrobial Agents, 2020, 56, 106008.	2.5	16
30	Comparing Circulating Tumor Cell Counts with Dynamic Tumor Size Changes as Predictor of Overall Survival: A Quantitative Modeling Framework. Clinical Cancer Research, 2020, 26, 4892-4900.	7.0	5
31	Model-based Dose Individualization of Sunitinib in Gastrointestinal Stromal Tumors. Clinical Cancer Research, 2020, 26, 4590-4598.	7.0	8
32	Combination of polymyxin B and minocycline against multidrug-resistant Klebsiella pneumoniae: interaction quantified by pharmacokinetic/pharmacodynamic modelling from in vitro data. International Journal of Antimicrobial Agents, 2020, 55, 105941.	2.5	13
33	Considerations for the optimal management of antibiotic therapy in elderly patients. Journal of Global Antimicrobial Resistance, 2020, 22, 325-333.	2.2	27
34	Model-Based Biomarker Selection for Dose Individualization of Tyrosine-Kinase Inhibitors. Frontiers in Pharmacology, 2020, 11, 316.	3.5	6
35	Pharmacodynamics of immune response biomarkers of interest for evaluation of treatment effects in bacterial infections. International Journal of Antimicrobial Agents, 2020, 56, 106059.	2.5	18
36	Model-Informed Drug Development in Pulmonary Delivery: Semimechanistic Pharmacokineticâ€"Pharmacodynamic Modeling for Evaluation of Treatments against Chronic <i>Pseudomonas aeruginosa</i> Lung Infections. Molecular Pharmaceutics, 2020, 17, 1458-1469.	4.6	8

#	Article	IF	Citations
37	Population pharmacokinetics of piperacillin in plasma and subcutaneous tissue in patients on continuous renal replacement therapy. International Journal of Infectious Diseases, 2020, 92, 133-140.	3.3	22
38	Tumor Time–Course Predicts Overall Survival in Non–Small Cell Lung Cancer Patients Treated with Atezolizumab: Dependency on Follow–Up Time. CPT: Pharmacometrics and Systems Pharmacology, 2020, 9, 115-123.	2.5	8
39	Colistin plus meropenem for carbapenem-resistant Gram-negative infections: in vitro synergism is not associated with better clinical outcomes. Clinical Microbiology and Infection, 2020, 26, 1185-1191.	6.0	46
40	Population pharmacokinetics of colistin and the relation to survival in critically ill patients infected with colistin susceptible and carbapenem-resistant bacteria. Clinical Microbiology and Infection, 2020, 26, 1644-1650.	6.0	22
41	Population Pharmacokinetics of Piperacillin following Continuous Infusion in Critically Ill Patients and Impact of Renal Function on Target Attainment. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	17
42	Efficacy of Antibiotic Combinations against Multidrug-Resistant Pseudomonas aeruginosa in Automated Time-Lapse Microscopy and Static Time-Kill Experiments. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	20
43	Evaluation of polymyxin B in combination with 13 other antibiotics against carbapenemase-producing Klebsiella pneumoniae in time-lapse microscopy and time-kill experiments. Clinical Microbiology and Infection, 2020, 26, 1214-1221.	6.0	26
44	A <scp>PK/PD</scp> Analysis of Circulating Biomarkers and Their Relationship to Tumor Response in Atezolizumab–Treated non–small cell Lung Cancer Patients. Clinical Pharmacology and Therapeutics, 2019, 105, 486-495.	4.7	23
45	Population pharmacokinetics of piperacillin in febrile children receiving cancer chemotherapy: the impact of body weight and target on an optimal dosing regimen. Journal of Antimicrobial Chemotherapy, 2019, 74, 2984-2993.	3.0	9
46	Effects of cladribine tablets on heart rate, atrio–ventricular conduction and cardiac repolarization in patients with relapsing multiple sclerosis. British Journal of Clinical Pharmacology, 2019, 85, 1484-1494.	2.4	6
47	Association between Paclitaxel Clearance and Tumor Response in Patients with Esophageal Cancer. Cancers, 2019, 11, 173.	3.7	1
48	A non-linear mixed effect model for innate immune response: In vivo kinetics of endotoxin and its induction of the cytokines tumor necrosis factor alpha and interleukin-6. PLoS ONE, 2019, 14, e0211981.	2.5	15
49	Piperacillin pharmacokinetics and target attainment in children with cancer and fever: Can we optimize our dosing strategy?. Pediatric Blood and Cancer, 2019, 66, e27654.	1.5	12
50	Model-Based Drug Development in Pulmonary Delivery: Pharmacokinetic Analysis of Novel Drug Candidates for Treatment of Pseudomonas aeruginosa Lung Infection. Journal of Pharmaceutical Sciences, 2019, 108, 630-640.	3.3	14
51	Treatment Outcomes of Colistin- and Carbapenem-resistant Acinetobacter baumannii Infections: An Exploratory Subgroup Analysis of a Randomized Clinical Trial. Clinical Infectious Diseases, 2019, 69, 769-776.	5.8	83
52	Population Pharmacokinetics of Piperacillin in Sepsis Patients: Should Alternative Dosing Strategies Be Considered?. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	29
53	Model-Based Adaptive Optimal Design (MBAOD) Improves Combination Dose Finding Designs: an Example in Oncology. AAPS Journal, 2018, 20, 39.	4.4	12
54	A Whole–Body Physiologically Based Pharmacokinetic Model for Colistin and Colistin Methanesulfonate in Rat. Basic and Clinical Pharmacology and Toxicology, 2018, 123, 407-422.	2.5	7

#	Article	IF	Citations
55	Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial. Lancet Infectious Diseases, The, 2018, 18, 391-400.	9.1	400
56	Semi-mechanistic pharmacokineticâ€"pharmacodynamic modelling of antibiotic drug combinations. Clinical Microbiology and Infection, 2018, 24, 697-706.	6.0	35
57	A Pharmacometric Analysis of Patient-Reported Outcomes in Breast Cancer Patients Through Item Response Theory. Pharmaceutical Research, 2018, 35, 122.	3.5	13
58	The Association Between Empirical Antibiotic Treatment and Mortality in Severe Infections Caused by Carbapenem-resistant Gram-negative Bacteria: A Prospective Study. Clinical Infectious Diseases, 2018, 67, 1815-1823.	5.8	29
59	Reply to Prim et al., â€œIs Colistin Susceptibility Testing Finally on the Right Track?â€ Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	2
60	Population Pharmacokinetics of Meropenem in Plasma and Subcutis from Patients on Extracorporeal Membrane Oxygenation Treatment. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	48
61	The risk of febrile neutropenia in breast cancer patients following adjuvant chemotherapy is predicted by the time course of interleukinâ€6 and Câ€reactive protein by modelling. British Journal of Clinical Pharmacology, 2018, 84, 490-500.	2.4	12
62	Predicting mutant selection in competition experiments with ciprofloxacin-exposed Escherichia coli. International Journal of Antimicrobial Agents, 2018, 51, 399-406.	2.5	4
63	Assessment of early combination effects of colistin and meropenem againstPseudomonas aeruginosaandAcinetobacter baumanniiin dynamic time-kill experiments. Infectious Diseases, 2017, 49, 521-527.	2.8	17
64	The role of infection models and PK/PD modelling for optimising care of critically ill patients with severe infections. Intensive Care Medicine, 2017, 43, 1021-1032.	8.2	100
65	Population Pharmacokinetic Modeling as a Tool To Characterize the Decrease in Ciprofloxacin Free Interstitial Levels Caused by Pseudomonas aeruginosa Biofilm Lung Infection in Wistar Rats. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	14
66	A whole-body physiologically based pharmacokinetic (WB-PBPK) model of ciprofloxacin: a step towards predicting bacterial killing at sites of infection. Journal of Pharmacokinetics and Pharmacodynamics, 2017, 44, 69-79.	1.8	33
67	Item Response Theory to Quantify Longitudinal Placebo and Paliperidone Effects on PANSS Scores in Schizophrenia. CPT: Pharmacometrics and Systems Pharmacology, 2017, 6, 543-551.	2.5	19
68	A Pharmacometric Framework for Axitinib Exposure, Efficacy, and Safety in Metastatic Renal Cell Carcinoma Patients. CPT: Pharmacometrics and Systems Pharmacology, 2017, 6, 373-382.	2.5	15
69	Pharmacometric Modeling of Liver Metastases' Diameter, Volume, and Density and Their Relation to Clinical Outcome in Imatinibâ€Treated Patients With Gastrointestinal Stromal Tumors. CPT: Pharmacometrics and Systems Pharmacology, 2017, 6, 449-457.	2.5	11
70	Can a pharmacokinetic/pharmacodynamic (PKPD) model be predictive across bacterial densities and strains? External evaluation of a PKPD model describing longitudinal in vitro data. Journal of Antimicrobial Chemotherapy, 2017, 72, 3108-3116.	3.0	23
71	Colistin Is Extensively Lost during Standard <i>In Vitro</i> Experimental Conditions. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	64
72	Advanced Methods for Dose and Regimen Finding During Drug Development: Summary of the EMA/EFPIA Workshop on Dose Finding (London 4â€"5 December 2014). CPT: Pharmacometrics and Systems Pharmacology, 2017, 6, 418-429.	2.5	52

#	Article	IF	Citations
73	Model-based prediction of myelosuppression and recovery based on frequent neutrophil monitoring. Cancer Chemotherapy and Pharmacology, 2017, 80, 343-353.	2.3	20
74	Models for change in tumour size, appearance of new lesions and survival probability in patients with advanced epithelial ovarian cancer. British Journal of Clinical Pharmacology, 2016, 82, 717-727.	2.4	20
75	Multicentre open-label randomised controlled trial to compare colistin alone with colistin plus meropenem for the treatment of severe infections caused by carbapenem-resistant Gram-negative infections (AIDA): a study protocol. BMJ Open, 2016, 6, e009956.	1.9	41
76	PK–PD modeling of individual lesion FDG–PET response to predict overall survival in patients with sunitinib–treated gastrointestinal stromal tumor. CPT: Pharmacometrics and Systems Pharmacology, 2016, 5, 173-181.	2.5	16
77	Challenge for higher colistin dosage in critically ill patients receiving continuous venovenous haemodiafiltration. International Journal of Antimicrobial Agents, 2016, 48, 337-341.	2.5	28
78	Simulation-Based Evaluation of PK/PD Indices for Meropenem Across Patient Groups and Experimental Designs. Pharmaceutical Research, 2016, 33, 1115-1125.	3.5	46
79	A pharmacokinetic–pharmacodynamic (PKPD) model based on *in vitro* time–kill data predicts the *in vivo* PK/PD index of colistin. Journal of Antimicrobial Chemotherapy, 2016, 71, 1881-1884.	3.0	26
80	Dynamic interaction of colistin and meropenem on a WT and a resistant strain of *Pseudomonas aeruginosa* as quantified in a PK/PD model. Journal of Antimicrobial Chemotherapy, 2016, 71, 1279-1290.	3.0	35
81	Inter occasion variability in individual optimal design. Journal of Pharmacokinetics and Pharmacodynamics, 2015, 42, 735-750.	1.8	6
82	Optimizing Oncology Therapeutics Through Quantitative Translational and Clinical Pharmacology: Challenges and Opportunities. Clinical Pharmacology and Therapeutics, 2015, 97, 37-54.	4.7	82
83	Performance of Nonlinear Mixed Effects Models in the Presence of Informative Dropout. AAPS Journal, 2015, 17, 245-255.	4.4	13
84	A pharmacokinetic binding model for bevacizumab and VEGF165 in colorectal cancer patients. Cancer Chemotherapy and Pharmacology, 2015, 75, 791-803.	2.3	46
85	A mechanism-based pharmacokinetic/pharmacodynamic model allows prediction of antibiotic killing from MIC values for WT and mutants. Journal of Antimicrobial Chemotherapy, 2015, 70, 3051-3060.	3.0	35
86	Colistin Population Pharmacokinetics after Application of a Loading Dose of 9 MU Colistin Methanesulfonate in Critically Ill Patients. Antimicrobial Agents and Chemotherapy, 2015, 59, 7240-7248.	3.2	93
87	Population pharmacokinetic–pharmacodynamic modelling in oncology: a tool for predicting clinical response. British Journal of Clinical Pharmacology, 2015, 79, 56-71.	2.4	82
88	Characterizing variability in warfarin dose requirements in children using modelling and simulation. British Journal of Clinical Pharmacology, 2014, 78, 158-169.	2.4	17
89	A pharmacokinetic/pharmacodynamic model developed for the effect of colistin on Pseudomonas aeruginosa in vitro with evaluation of population pharmacokinetic variability on simulated bacterial killing. Journal of Antimicrobial Chemotherapy, 2014, 69, 1350-1361.	3.0	44
90	Characterization of Endogenous G-CSF and the Inverse Correlation to Chemotherapy-Induced Neutropenia in Patients with Breast Cancer Using Population Modeling. Pharmaceutical Research, 2014, 31, 3390-3403.	3.5	45

#	Article	IF	Citations
91	A Mechanistic Pharmacokinetic Model Elucidating the Disposition of Trastuzumab Emtansine (T-DM1), an Antibody–Drug Conjugate (ADC) for Treatment of Metastatic Breast Cancer. AAPS Journal, 2014, 16, 994-1008.	4.4	72
92	A Review of Mixed–Effects Models of Tumor Growth and Effects of Anticancer Drug Treatment Used in Population Analysis. CPT: Pharmacometrics and Systems Pharmacology, 2014, 3, 1-10.	2.5	137
93	<i>CPT: Pharmacometrics & Systems Pharmacology</i> Publishes Its 100th Article. CPT: Pharmacometrics and Systems Pharmacology, 2014, 3, 1-2.	2.5	1
94	Simultaneous Exposure–Response Modeling of ACR20, ACR50, and ACR70 Improvement Scores in Rheumatoid Arthritis Patients Treated With Certolizumab Pegol. CPT: Pharmacometrics and Systems Pharmacology, 2014, 3, 1-11.	2.5	26
95	Warfarin dose prediction in children using pharmacometric bridging—comparison with published pharmacogenetic dosing algorithms. European Journal of Clinical Pharmacology, 2013, 69, 1275-1283.	1.9	36
96	Predictions of In Vivo Prolactin Levels from In Vitro K i Values of D2 Receptor Antagonists Using an Agonist–Antagonist Interaction Model. AAPS Journal, 2013, 15, 533-541.	4.4	5
97	Systematic Review and Meta-Analysis of <i>In Vitro</i> Synergy of Polymyxins and Carbapenems. Antimicrobial Agents and Chemotherapy, 2013, 57, 5104-5111.	3.2	202
98	Pharmacokinetic-Pharmacodynamic Modeling of Antibacterial Drugs. Pharmacological Reviews, 2013, 65, 1053-1090.	16.0	248
99	A Pharmacogenetic Predictive Model for Paclitaxel Clearance Based on the DMET Platform. Clinical Cancer Research, 2013, 19, 5210-5217.	7.0	23
100	PKPD Modeling of Predictors for Adverse Effects and Overall Survival in Sunitinib–Treated Patients With GIST. CPT: Pharmacometrics and Systems Pharmacology, 2013, 2, 1-9.	2.5	43
101	PKPD Modeling of VEGF, sVEGFR–2, sVEGFR–3, and sKIT as Predictors of Tumor Dynamics and Overall Survival Following Sunitinib Treatment in GIST. CPT: Pharmacometrics and Systems Pharmacology, 2013, 2, 1-9.	2.5	53
102	Longitudinal infusion of a complex of insulin-like growth factor-I and IGF-binding protein-3 in five preterm infants: pharmacokinetics and short-term safety. Pediatric Research, 2013, 73, 68-74.	2.3	58
103	<i>CYP3A4*22</i> Genotype and Systemic Exposure Affect Paclitaxel-Induced Neurotoxicity. Clinical Cancer Research, 2013, 19, 3316-3324.	7.0	88
104	Colistin Methanesulfonate and Colistin Pharmacokinetics in Critically Ill Patients Receiving Continuous Venovenous Hemodiafiltration. Antimicrobial Agents and Chemotherapy, 2013, 57, 668-671.	3.2	71
105	Tutorials on the Foundations of Pharmacometrics and Systems Pharmacology. CPT: Pharmacometrics and Systems Pharmacology, 2013, 2, 1-2.	2.5	2
106	Pharmacometrics and Systems Pharmacology Software Tutorials and Use: Comments and Guidelines for PSP Contributions. CPT: Pharmacometrics and Systems Pharmacology, 2013, 2, 86.	2.5	3
107	A Long-term Prospective Population Pharmacokinetic Study on Imatinib Plasma Concentrations in GIST Patients. Clinical Cancer Research, 2012, 18, 5780-5787.	7.0	96
108	Influence of Polymorphic OATP1B-Type Carriers on the Disposition of Docetaxel. Clinical Cancer Research, 2012, 18, 4433-4440.	7.0	80

#	ARTICLE	IF	CITATIONS
109	Pharmacokinetic-Pharmacodynamic Model for Gentamicin and Its Adaptive Resistance with Predictions of Dosing Schedules in Newborn Infants. Antimicrobial Agents and Chemotherapy, 2012, 56, 179-188.	3.2	71
110	Integrated Population Pharmacokinetic Analysis of Voriconazole in Children, Adolescents, and Adults. Antimicrobial Agents and Chemotherapy, 2012, 56, 3032-3042.	3.2	133
111	Influence of Smoking on the Pharmacokinetics and Toxicity Profiles of Taxane Therapy. Clinical Cancer Research, 2012, 18, 4425-4432.	7.0	34
112	Pharmacokineticâ€"Pharmacodynamic Modeling of Severity Levels of Extrapyramidal Side Effects With Markov Elements. CPT: Pharmacometrics and Systems Pharmacology, 2012, 1, 1-9.	2.5	23
113	420 Increased Clearance of Docetaxel in Androgen Deprived Prostate Cancer Patients. European Journal of Cancer, 2012, 48, 128.	2.8	0
114	Acute organophosphorus poisoning in humans: A PK model for chlorpyrifos. Toxicology Letters, 2012, 211, S173.	0.8	1
115	A population pharmacokinetic/pharmacodynamic model of thrombocytopenia characterizing the effect of trastuzumab emtansine (T-DM1) on platelet counts in patients with HER2-positive metastatic breast cancer. Cancer Chemotherapy and Pharmacology, 2012, 70, 591-601.	2.3	72
116	Application of a Loading Dose of Colistin Methanesulfonate in Critically Ill Patients: Population Pharmacokinetics, Protein Binding, and Prediction of Bacterial Kill. Antimicrobial Agents and Chemotherapy, 2012, 56, 4241-4249.	3.2	201
117	Evaluation of IPPSE, an alternative method for sequential population PKPD analysis. Journal of Pharmacokinetics and Pharmacodynamics, 2012, 39, 177-193.	1.8	25
118	The shape of the myelosuppression time profile is related to the probability of developing neutropenic fever in patients with docetaxel-induced grade IV neutropenia. Cancer Chemotherapy and Pharmacology, 2012, 69, 881-890.	2.3	24
119	Population pharmacokinetics of cytarabine, etoposide, and daunorubicin in the treatment for acute myeloid leukemia. Cancer Chemotherapy and Pharmacology, 2012, 69, 1155-1163.	2.3	29
120	A simultaneous analysis of the time-course of leukocytes and neutrophils following docetaxel administration using a semi-mechanistic myelosuppression model. Investigational New Drugs, 2012, 30, 833-845.	2.6	57
121	Pharmacokinetic/Pharmacodynamic (PK/PD) Indices of Antibiotics Predicted by a Semimechanistic PKPD Model: a Step toward Model-Based Dose Optimization. Antimicrobial Agents and Chemotherapy, 2011, 55, 4619-4630.	3.2	198
122	Impact of CYP2C8*3 on paclitaxel clearance: a population pharmacokinetic and pharmacogenomic study in 93 patients with ovarian cancer. Pharmacogenomics Journal, 2011, 11, 113-120.	2.0	81
123	Predictive ability of a semi-mechanistic model for neutropenia in the development of novel anti-cancer agents: two case studies. Investigational New Drugs, 2011, 29, 984-995.	2.6	22
124	Influence of Cremophor EL and Genetic Polymorphisms on the Pharmacokinetics of Paclitaxel and Its Metabolites Using a Mechanism-Based Model. Drug Metabolism and Disposition, 2011, 39, 247-255.	3.3	32
125	Predicting <i>In Vitro</i> Antibacterial Efficacy across Experimental Designs with a Semimechanistic Pharmacokinetic-Pharmacodynamic Model. Antimicrobial Agents and Chemotherapy, 2011, 55, 1571-1579.	3.2	40
126	CORRECTION TO â€œInfluence of Cremophor EL and Genetic Polymorphisms on the Pharmacokinetics of Paclitaxel and Its Metabolites Using a Mechanism-Based Modelâ€‌ TABLE 3. Drug Metabolism and Disposition, 2011, 39, 563-563.	3.3	0

#	ARTICLE	IF	CITATIONS
127	Limited inter-occasion variability in relation to inter-individual variability in chemotherapy-induced myelosuppression. Cancer Chemotherapy and Pharmacology, 2010, 65, 839-848.	2.3	20
128	Transforming parts of a differential equations system to difference equations as a method for run-time savings in NONMEM. Journal of Pharmacokinetics and Pharmacodynamics, 2010, 37, 493-506.	1.8	1
129	Scaling the time-course of myelosuppression from rats to patients with a semi-physiological model. Investigational New Drugs, 2010, 28, 744-753.	2.6	40
130	Model‐Based Neutrophil‐Guided Dose Adaptation in Chemotherapy: Evaluation of Predicted Outcome with Different Types and Amounts of Information. Basic and Clinical Pharmacology and Toxicology, 2010, 106, 234-242.	2.5	33
131	Comparison of the agonist‐antagonist interaction model and the pool model for the effect of remoxipride on prolactin. British Journal of Clinical Pharmacology, 2010, 70, 815-824.	2.4	11
132	A Semi‐Mechanistic Model of CP‐690,550‐Induced Reduction in Neutrophil Counts in Patients With Rheumatoid Arthritis. Journal of Clinical Pharmacology, 2010, 50, 679-687.	2.0	17
133	A CYP3A4 Phenotype–Based Dosing Algorithm for Individualized Treatment of Irinotecan. Clinical Cancer Research, 2010, 16, 736-742.	7.0	63
134	Modelling the genesis and treatment of cancer: The potential role of physiologically based pharmacodynamics. European Journal of Cancer, 2010, 46, 21-32.	2.8	11
135	Dose response of whole-grain biomarkers: alkylresorcinols in human plasma and their metabolites in urine in relation to intake. American Journal of Clinical Nutrition, 2009, 89, 290-296.	4.7	97
136	A Pharmacokinetic and Dosing Study of Intravenous Insulin-Like Growth Factor-I and IGF-Binding Protein-3 Complex to Preterm Infants. Pediatric Research, 2009, 65, 574-579.	2.3	54
137	A tool for neutrophil guided dose adaptation in chemotherapy. Computer Methods and Programs in Biomedicine, 2009, 93, 283-291.	4.7	34
138	An Agonist–Antagonist Interaction Model for Prolactin Release Following Risperidone and Paliperidone Treatment. Clinical Pharmacology and Therapeutics, 2009, 85, 409-417.	4.7	24
139	The Effect of Decontamination Procedures on the Pharmacokinetics of Venlafaxine in Overdose. Clinical Pharmacology and Therapeutics, 2009, 86, 403-410.	4.7	29
140	A Pharmacodynamic Markov Mixed-Effects Model for Determining the Effect of Exposure to Certolizumab Pegol on the ACR20 Score in Patients With Rheumatoid Arthritis. Clinical Pharmacology and Therapeutics, 2009, 86, 387-395.	4.7	48
141	Modeling and Simulation of the Time Course of Asenapine Exposure Response and Dropout Patterns in Acute Schizophrenia. Clinical Pharmacology and Therapeutics, 2009, 86, 84-91.	4.7	55
142	Quantitative analysis of colistin A and colistin B in plasma and culture medium using a simple precipitation step followed by LC/MS/MS. Journal of Pharmaceutical and Biomedical Analysis, 2009, 49, 760-767.	2.8	94
143	Population Pharmacokinetic Analysis of Colistin Methanesulfonate and Colistin after Intravenous Administration in Critically Ill Patients with Infections Caused by Gram-Negative Bacteria. Antimicrobial Agents and Chemotherapy, 2009, 53, 3430-3436.	3.2	448
144	Developmental Pharmacokinetics of Gentamicin in Preterm and Term Neonates. Clinical Pharmacokinetics, 2009, 48, 253-263.	3.5	71

#	Article	IF	Citations
145	Population Pharmacokinetics of Tacrolimus in Pediatric Hematopoietic Stem Cell Transplant Recipients: New Initial Dosage Suggestions and a Model-Based Dosage Adjustment Tool. Therapeutic Drug Monitoring, 2009, 31, 457-466.	2.0	38
146	Cigarette Smoking and Irinotecan Treatment: Pharmacokinetic Interaction and Effects on Neutropenia. Journal of Clinical Oncology, 2007, 25, 2719-2726.	1.6	115
147	Human methyl parathion poisoning. Clinical Toxicology, 2007, 45, 956-960.	1.9	22
148	Activated Charcoal Decreases the Risk of QT Prolongation After Citalopram Overdose. Annals of Emergency Medicine, 2007, 50, 593-600.e46.	0.6	48
149	Irinotecan-induced Diarrhea: Functional Significance of the Polymorphic ABCC2 Transporter Protein. Clinical Pharmacology and Therapeutics, 2007, 81, 42-49.	4.7	164
150	Pharmacokinetics of Quetiapine in Overdose and the Effect of Activated Charcoal. Clinical Pharmacology and Therapeutics, 2007, 81, 821-827.	4.7	48
151	Reply to Dr. Mégarbane et al. regarding "Pharmacokinetic/pharmacodynamic modelling of cardiac toxicity in venlafaxine overdose". Intensive Care Medicine, 2007, 33, 197-197.	8.2	5
152	Application of pharmacokinetic-pharmacodynamic modeling in management of QT abnormalities after citalopram overdose. Reply to A. Manini. Intensive Care Medicine, 2007, 33, 739-739.	8.2	0
153	Population Pharmacokinetics of Itraconazole and its Active Metabolite Hydroxy-Itraconazole in Paediatric Cystic Fibrosis and Bone Marrow Transplant Patients. Clinical Pharmacokinetics, 2006, 45, 1099-1114.	3.5	54
154	Pharmacokinetic-pharmacodynamic modelling of QT interval prolongation following citalopram overdoses. British Journal of Clinical Pharmacology, 2006, 61, 177-190.	2.4	77
155	PII-20Irinotecan (CPT-11) related diarrhea: Functional significance of the polymorphic ABCC2 transporter protein. Clinical Pharmacology and Therapeutics, 2006, 79, P41-P41.	4.7	0
156	Application of pharmacokinetic-pharmacodynamic modelling in management of QT abnormalities after citalopram overdose. Intensive Care Medicine, 2006, 32, 1060-1065.	8.2	52
157	Pharmacokinetic/Pharmacodynamic Modelling in Oncological Drug Development. Basic and Clinical Pharmacology and Toxicology, 2005, 96, 206-211.	2.5	34
158	Pharmacokinetic–pharmacodynamic modelling of the schedule-dependent effect of the anti-cancer agent CHS 828 in a rat hollow fibre model. European Journal of Pharmaceutical Sciences, 2005, 25, 163-173.	4.0	10
159	The Population Pharmacokinetics of Citalopram After Deliberate Self-Poisoning: A Bayesian Approach. Journal of Pharmacokinetics and Pharmacodynamics, 2005, 32, 571-605.	1.8	65
160	Prediction of Irinotecan Pharmacokinetics by Use of Cytochrome P450 3A4 Phenotyping Probes. Journal of the National Cancer Institute, 2004, 96, 1585-1592.	6.3	113
161	Pharmacodynamic differences between species exemplified by the novel anticancer agent CHS 828. Drug Development Research, 2004, 61, 218-226.	2.9	4
162	Mechanistic models for myelosuppression. Investigational New Drugs, 2003, 21, 183-194.	2.6	87

#	ARTICLE	IF	CITATIONS
163	Model of Chemotherapy-Induced Myelosuppression With Parameter Consistency Across Drugs. Journal of Clinical Oncology, 2002, 20, 4713-4721.	1.6	436
164	In vivo activity of CHS 828 on hollow-fibre cultures of primary human tumour cells from patients. Cancer Letters, 2001, 162, 193-200.	7.2	16
165	Models of schedule dependent haematological toxicity of 2'-deoxy-2'-methylidenecytidine (DMDC). European Journal of Clinical Pharmacology, 2000, 56, 567-574.	1.9	37
166	Determination of drug effect on tumour cells, host animal toxicity and drug pharmacokinetics in a hollow-fibre model in rats. Cancer Chemotherapy and Pharmacology, 2000, 46, 493-500.	2.3	26
167	The pharmacokinetics of epirubicin and docetaxel in combination in rats. Cancer Chemotherapy and Pharmacology, 1999, 44, 469-474.	2.3	14
168	Bayesian Hierarchical Modeling with Markov Chain Monte Carlo Methods. , 0, , 137-164.		5